Summit Therapeutics (SMMT) Income towards Parent Company (2016 - 2024)
Historic Income towards Parent Company for Summit Therapeutics (SMMT) over the last 8 years, with Q4 2024 value amounting to -$65.6 million.
- Summit Therapeutics' Income towards Parent Company fell 8122.89% to -$65.6 million in Q4 2024 from the same period last year, while for Sep 2025 it was -$65.6 million, marking a year-over-year increase of 3237.67%. This contributed to the annual value of -$234.7 million for FY2024, which is 6183.55% up from last year.
- Latest data reveals that Summit Therapeutics reported Income towards Parent Company of -$65.6 million as of Q4 2024, which was down 8122.89% from -$60.8 million recorded in Q3 2024.
- Summit Therapeutics' 5-year Income towards Parent Company high stood at -$9.0 million for Q1 2020, and its period low was -$65.6 million during Q4 2024.
- For the 4-year period, Summit Therapeutics' Income towards Parent Company averaged around -$32.8 million, with its median value being -$20.5 million (2023).
- Per our database at Business Quant, Summit Therapeutics' Income towards Parent Company skyrocketed by 124.15% in 2020 and then crashed by 19685.73% in 2024.
- Quarter analysis of 4 years shows Summit Therapeutics' Income towards Parent Company stood at -$9.0 million in 2020, then tumbled by 125.55% to -$20.3 million in 2022, then plummeted by 78.38% to -$36.2 million in 2023, then crashed by 81.23% to -$65.6 million in 2024.
- Its Income towards Parent Company stands at -$65.6 million for Q4 2024, versus -$60.8 million for Q3 2024 and -$36.2 million for Q4 2023.